Artiva Biotherapeutics (ARTV) EBITDA (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly EBITDA of -$24.4 million for Q1 2026, down 10.19% year-over-year from -$27.2 million in Q1 2025, and down 11.39% quarter-over-quarter from -$21.9 million in Q4 2025.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) EBITDA (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported EBITDA for 4 consecutive years, with -$24.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 10.19% year-over-year to -$24.4 million; the TTM figure through Mar 2026 stood at -$92.1 million (down 22.82% YoY), while the FY2025 annual figure was -$89.8 million, down 33.48% from the prior year.
- EBITDA retreated to -$24.4 million in Q1 2026 per ARTV's latest filing, from -$21.9 million in the prior quarter.
- Across five years, EBITDA topped out at $10.8 million in Q3 2023 and bottomed at -$24.4 million in Q1 2026.
- Historically, EBITDA has averaged -$16.2 million across 4 years, with a median of -$18.3 million in 2024.
- Annual changes were most pronounced in 2024 — EBITDA slumped 269.6% — and 2026, when it dropped 10.19%.
- Artiva Biotherapeutics' EBITDA stood at -$12.0 million in 2023, then sank by 52.61% to -$18.3 million in 2024, then slipped by 20.06% to -$21.9 million in 2025, then dropped by 11.39% to -$24.4 million in 2026.
- Business Quant data shows ARTV's EBITDA at -$24.4 million in Q1 2026, -$21.9 million in Q4 2025, and -$22.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Artiva Biotherapeutics | 441.82 Mn | 441.82 Mn | - | -26.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.89 Mn |
| Mar 31, 2026 | -24.43 Mn |
| Dec 31, 2025 | -21.93 Mn |
| Sep 30, 2025 | -22.90 Mn |
| Jun 30, 2025 | -22.81 Mn |
| Mar 31, 2025 | -22.17 Mn |
| Dec 31, 2024 | -18.27 Mn |
| Sep 30, 2024 | -18.34 Mn |
| Jun 30, 2024 | -16.19 Mn |
| Mar 31, 2024 | -14.49 Mn |
| Dec 31, 2023 | -11.97 Mn |
| Sep 30, 2023 | 10.81 Mn |
| Jun 30, 2023 | -11.82 Mn |